Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Allegro Ophthalmics

Request full access

Treating vitreoretinal diseases

San Juan Capistrano, United StatesFounded 2009Biotech & Life Sciences

About Allegro Ophthalmics

Allegro Ophthalmics is pioneering the treatment of ocular diseases through innovative integrin inhibition therapies. The company focuses on developing treatments for conditions such as Dry Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Dry Eye Disease. Allegro's primary clientele includes ophthalmologists and healthcare providers specializing in eye care, as well as patients suffering from these debilitating eye conditions. Operating in the biopharmaceutical market, Allegro leverages cutting-edge clinical research to bring novel therapies from theory to therapy.

The business model of Allegro Ophthalmics revolves around the development and commercialization of its proprietary drug candidates. The company generates revenue through the successful advancement of its drug pipeline, securing partnerships, and potentially licensing its technologies to larger pharmaceutical companies. Allegro's integrin regulating portfolio, particularly its lead candidate Risuteganib, is currently in various stages of clinical trials, showcasing promising results in improving visual function and halting disease progression.

Allegro's commitment to rigorous clinical research and its strategic focus on unmet medical needs position it as a key player in the ophthalmic treatment landscape. By continuously presenting its findings at major ophthalmology conferences, the company maintains a strong presence in the scientific community and keeps stakeholders informed about its progress.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
57.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Ophthalmology, Eye Diseases, Spinout, Biotech and Pharma, DT and LS, science-based

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Jul 2017 $11M $43M Undisclosed ↗
GRANTOther financing Feb 2015 $2M — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Allegro Ophthalmics website traffic

Latest recorded traffic for Allegro Ophthalmics is 1.3K monthly website visits, up 400% over the last three months. Allegro Ophthalmics's team declined 40% over the past year.

Latest monthly visits1.3K 3-month web change+400% 1-year team growth-40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Allegro Ophthalmics in the San Juan Capistrano ecosystem

Live from Dealroom

The Allegro Ophthalmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Hanmi Pharmaceutical

Other known investors1 additional known investor

  • Caltech, California Institute of Technology
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Allegro Ophthalmics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Allegro Ophthalmics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.